INDICATIONS AND USAGE
AMPYRA™ (dalfampridine) is a potassium channel blocker indicated to improve
walking in patients with multiple sclerosis (MS). This was demonstrated by an
increase in walking speed
DOSAGE AND ADMINISTRATION
Maximum recommended dose: 10 mg twice daily (approximately 12 hours apart) with
or without food.
Patients should not take double or extra doses if a dose is missed. No
additional benefit was demonstrated at doses greater than 10 mg twice daily and
adverse events, including seizures, were more frequent at higher doses.
Tablets should only be taken whole; do not divide, crush, chew, or dissolve.
DOSAGE FORMS AND STRENGTHS
10 mg tablets
AMPYRA is contraindicated in patients with moderate or severe renal
impairment. The risk of seizures in patients with mild renal impairment
(CrCl 51-80 mL/min) is unknown, but AMPYRA plasma exposure in these
patients may approach that seen at a dose of 15 mg twice daily, a dose
that may be associated with an increased risk of seizures; estimated
CrCl should be known before initiating treatment with AMPYRA.
Contraindicated. Do not use.
National Institutes of Health, U.S. National Library of Medicine,
DailyMed Database. Provides access to the latest drug monographs submitted to the
Food and Drug Administration (FDA). Please review the latest applicable package insert for
additional information and possible updates. A local search
option of this data can be found here.
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical
judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material.PLEASE READ THE DISCLAIMER
BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU
AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read